Table 2.
Nucleotide aptamers in development with potential for use in targeting of shRNA therapy
| Aptamer | Target | Testing
|
||
|---|---|---|---|---|
| in vitro | in vivo | Clinical | ||
| AS1411 (Agro100) | Nucleolin | antiproliferation, growth inhibition | Antitumor activity in nude mouse xenograft models, synergy with chemotherapeutic agents | Phase 1 and 2 trials for advanced solid malignancies |
| TTA1 | TN-C | Binding | Sucessful aptamer penetration in various murine xenograft tumor models | not tested |
| various | MUC1 | Binding | Sucessful aptamer penetration in a murine xenograft tumor model | not tested |
| xPSM-A10 | PSMA | Inhbition of PSMA via competetive binding | Sucessful targeting of a chemotherapy nanoparticle in a murine xenograft model | not tested |
| xPSM-A9 | PSMA | Inhbition of PSMA via noncompetetive binding | not tested | not tested |
| A30 | HER3 | Inhibitor of HER-3 signaling via noncompetetive binding | not tested | not tested |
| D4 | RETC634Y | Inhibitor of RETC634Y dimer formation | not tested | not tested |